Dear Investors ,

Since the start of 2020, we have all had to adjust to new living, learning and working environments that the COVID-19 pandemic has imposed on us with little or no warning. Some of you may be familiar with the last major pandemic that came in the form of the Spanish Flu a century ago and which infected almost 30% of the global population or 500 million people, with a mortality rate around 10% or 50 million deaths. At a current world population just shy of 8 billion, the very grim prospect of COVID-19 developing into a similar global health disaster is unacceptable. The current global 0.23% infection and 0.009% mortality rates should leave no room for any complacency or sense of achievement. The pandemic ravages through North and South Americas, Indian subcontinent and Africa with unimaginable consequences. Elsewhere, the sense of relief witnessed after relaxation of strict isolation protocols has only been savagely eclipsed by significant secondary surges. In this surreal twilight, it is impossible to say if the night is approaching or has passed us by. Certainly, a new clean morning seems a long way off.

Neither a continued sense of utter hopelessness nor a wishful and reassuring indulgence that this crisis will simply and miraculously disappear are helpful in getting us back to normality. What we can and must do is proactively work on or support a treatment solution to combat COVID-19 and save lives, which now means far more than just treating an individual back to health. The added impact of failing economies on livelihoods and mental health is becoming incalculable. It is with a spirit of necessary and pro-active optimism that our group of professionals were brought together in early 2020 to focus on re-purposing existing therapeutics to provide treatment solutions for COVID-19. Through many months of trial and tribulation since early 2020, and with an expanded team recently, we are delighted to have now identified a portfolio of anti viral and anti inflammatory drug candidates that we believe will provide the effective treatment solutions for COVID-19.

Our team consists of professionals with strong experience in healthcare, drug development, drug synthesis and testing, drug delivery expertise particularly in oral inhalation, corporate governance and investment banking. Our team also has significant trusted relationships with healthcare professionals in a number of countries severely affected by COVID-19 including Australia, India, South America, Africa, Hong Kong, and China that will enable us to establish collaborative projects in these countries including conducting clinical trials.

We are currently raising investment capital to expand our business and drug development programs. We plan to list our company on an Australian stock exchange in 2021 after we have filed provisional patents for our Intellectual Properties, proven the efficacy of our therapeutics against COVID-19, and started the commercialization process. We expect to file the initial provisional patent within the next month. COVIRIX Medical is an emerging pharmaceutical company that has been established by one of Australia's best teams of professionals with highly complementary expertise at a very critical time for the world. Our mission is to develop effective therapeutics to treat COVID-19, save lives, and lessen the misery affecting individuals, families and society at large.

I look forward to your investment interest and support.

Regards,

Kumud Dhital